- Details
- Neeraj Agarwal speaks with Umang Swami about treatment patterns in metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Swami presents encouraging findings from a large retrospective study using the Flatiron Health database of 14,000 patients showing that ADT intensification therapies have risen dramatically from just 40% a few years ago to 77% since January 2023. The data reveals that approx...
|
- Details
- Neeraj Agarwal speaks with Hannah McManus about research from the IRONMAN registry examining PSA responses and outcomes in metastatic hormone-sensitive prostate cancer patients. Dr. McManus discusses findings from over 1,300 real-world patients across four countries receiving different treatment regimens. The study reveals that patients achieving undetectable PSA nadirs ( 50%) observed in the ADT...
|
- Details
- Neeraj Agarwal is joined by Fred Saad to discuss PSA responses in the ARANOTE trial of darolutamide plus ADT in metastatic hormone-sensitive prostate cancer. Dr. Saad explains how darolutamide triples the rate of patients achieving undetectable PSA ( 21 (≈50%). This translates to numerically better progression-free survival in patients starting with lower PSA values. Dr. Saad describes practical a...
|
- Details
- Neeraj Agarwal is joined by Alicia Morgans to discuss an analysis of baseline PSA levels and clinical outcomes from the ARASENS trial in metastatic hormone-sensitive prostate cancer. Dr. Morgans explains how the study stratified patients into low ( 27.55) PSA quartiles to assess the impact of adding darolutamide to ADT plus docetaxel. Across all PSA levels, the darolutamide triplet achieved signif...
|
- Details
- Neeraj Agarwal is joined by Arun Azad to discuss preliminary findings from the LIBERTAS trial. This de-escalation study in metastatic hormone-sensitive prostate cancer gives patients six months of ADT plus apalutamide before those achieving undetectable PSA (
|
- Details
- Neeraj Agarwal hosts Emmanuel Antonarakis to discuss research on PARP1 expression and PARP inhibitor response in prostate cancer. Dr. Antonarakis shares an analysis of 50,000 transcriptomes revealing that high PARP1 and PARP2 expression correlates with aggressive features and faster metastasis, while PARP6 and PARP7 overexpression indicates better outcomes. The most relevant finding came from a bi...
|
- Details
- Neeraj Agarwal is joined by Nicolas Sayegh to discuss research investigating whether time from prostatectomy to metastasis affects survival in metastatic hormone-sensitive prostate cancer. Analyzing data from 301 patients in the SWOG S1216 trial, Dr. Sayegh found no correlation between this duration and survival outcomes, whether analyzed continuously or in thresholds of 1-4 years. These findings...
|
- Details
- Neeraj Agarwal hosts Irbaz Riaz and Syed Arsalan Naqvi to discuss a meta-analysis on ARPI selection in metastatic hormone-sensitive prostate cancer. Dr. Naqvi presents findings analyzing data from six trials with 7,000 patients, showing no significant efficacy differences among abiraterone, apalutamide, enzalutamide, and darolutamide across disease volumes and metastatic timing. Treatment selectio...
|
- Details
- Neeraj Agarwal is joined by Giulio Francolini to discuss the Persian trial examining SBRT added to ADT plus apalutamide in oligometastatic hormone-sensitive prostate cancer. Dr. Francolini explains this 180-patient randomized study was designed to clarify SBRT's benefits in patients with up to five non-visceral metastases, a treatment approach already common in practice despite limited evidence. P...
|
- Details
- Neeraj Agarwal speaks with Zeynep Ozay about research on the impact of statins in patients with advanced prostate cancer treated with apalutamide. Dr. Ozay shares findings from a pooled patient-level analysis of the TITAN and SPARTAN trials, which included 2,190 patients receiving either ADT alone or ADT plus apalutamide. The multivariable analysis reveals that patients taking statins alongside ap...
|
